Novo Nordisk wins big on strong US dollar

The sharply rising US dollar exchange rate compared to the Danish krone is very lucrative for Danish firms. Novo Nordisk is the clear winner, but many other healthcare companies also stand to benefit.

Photo: Jacob Gronholt-Pedersen/REUTERS / X04292

Danish business, with pharmaceutical flagship Novo Nordisk at the forefront, is winning big on a dramatic rise in the US dollar exchange rate.

This year alone, the US dollar has increased in value by nearly 10 percent compared to the Danish krone, and many of the leading companies in Denmark have benefitted from this change.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

In a world of options, Genmab's CEO chose partnerships

In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.

Further reading

Related articles

Latest news

See all jobs